CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
KAE609drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01836458
NCT01836458Phase 2Completed
CompareCT.gov

An Open-label Study to Find the Minimum Inhibitory Concentration(MIC) of KAE609 in Adult Male Patients With Acute, Uncomplicated Malaria Due to Plasmodium Falciparum Monoinfection

Novartis Pharmaceuticals·interventional·Posted Apr 19, 2013·Updated Oct 31, 2016

In Brief

A Phase 2 clinical trial evaluating KAE609 for Malaria. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This study aims to determine the Minimum Inhibitory Concentration of KAE609 in adult male patients with acute, uncomplicated malaria due to P.falciparum monoinfection after single dosing with KAE609

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesVietnam
Collaborators--

Timeline

Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 19, 2013
Enrollment StartJan 1, 2014
Primary CompletionMar 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 13.2 years ago

Interventions

KAE609drug

Patients will receive KAE609 single dose at a different dose level in each cohort.